Tauriga Sciences Inc (fka TAUG)

[Johnny_C]

Looks like one of those share issuance and convertible notes might have resulted in Seth using $350,000 to strike GOLD. For instance, as far as I know TAUG is the only public entity that has a stake in Aegea (that may have changed in the past 6 months, I am not sure).

If Aegea's test takes off TAUG's investment in Aegea could be worth as much as the TAUG's current market cap!

Aegea seems to have a test that not only is extremely accurate in diagnosing COVID, but can tell the difference between the flu and different variants.

Currently, there are 350,000 DAILY tests alone in the U.S.

Does anyone think Quest or Thermal Fisher will want this test? To get an EUA the FDA now wants a company to be able to be capable of producing 500,000 tests a week. Aegea does not have that capability. They need a big partner.

Also, previously, Aegea told me that this type of test gets a $400 dollar reimbursement as opposed to a $100 reimbursement. I am not sure if that still holds, given the emphasis on home kits, but this test will certainly command more than a normal lab test.

Seth never gets any credit for the good moves he has made, and IMO he has made more good moves than bad trying to put Tauriga in a position to be very successful! This Company started from scratch 2 1/2 years ago.

Aegea could very well become a 1/2 billion dollar company overnight.

Just in the US over 10 million tests are done a month, if Aegea, through a large partner captures just 20% of that business and sells the test for $25 they could generate $50 million dollars a month in revenue.

Aegea also owns multiple switch blocker patents for disease testing. many are very valuable and are just sitting dormant because they have not been discovered. One test, is very highly rated by doctors and hospitals, but unfortunately, Biocept has not been able to commercialize it properly.

The liquid biopsy market is huge! Aegea will get quite a bit of attention in the next few months especially with new variants in the news. That has to draw interest to the other IP's they have. Aegea's CEO is in his 70's so I would think a buyout is a consideration over the next couple years..

https://www.medtechdive.com/news/illumina-inks-8b-grail-buyout-for-liquid-biopsy-market-investors-are-not/585584/


https://www.genomeweb.com/business-news/agilent-technologies-acquire-liquid-biopsy-firm-resolution-bioscience-695m#.YaIlUtDMLZs

Anyway, what is your analysis of this current turn of events?